Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing ...

A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause mortality between intensive chemotherapy and azacitidine plus venetoclax, but ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.

The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 2 study titled ‘A ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

SELLAS Life Sciences (SLS) stock gains as a Phase 2 trial for its cancer drug SLS009 succeds in patients with acute myeloid ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most ...